Table 1.
ROC Analysis for Prediction of Response (OS > 11 Months)
| ROC AUC [asymptotic 95% CI] |
P-value | Optimal cutoff | Sensitivity (%) | Specificity (%) | Overall survival HR [95% CI] |
P-value | |
|---|---|---|---|---|---|---|---|
| MTV follow-up (mL) | 0.771 [0.511–1.000] | (.041) | 18.3 | 70 | 100 | 1.031 [1.011–1.052] | (.002) |
| ΔMTV (mL) | 0.757 [0.515–0.999] | (.037) | −5.3 | 70 | 86 | 1.023 [1.005–1.041] | (.006) |
| ΔTBRmax (a.u.) | 0.814 [0.595–1.000] | (.005) | −0.53 | 70 | 100 | 2.807 [1.173–4.714] | (.020) |
| rΔTBRmax (%) | 0.829 [0.613–1.000] | (.003) | −11 | 70 | 100 | 1.034 [1.008–1.062] | (.012) |
| PRMplus (mL) | 0.843 [0.634–1.000] | (.001) | 4.0 | 80 | 100 | 1.040 [1.013–1.068] | (.003) |
| PRMnet (mL) | 0.757 [0.512–1.000] | (.040) | −5.6 | 70 | 86 | 1.019 [1.000–1.035] | (.019) |
Abbreviations: MTV, [18F]FET metabolically active volume; TBRmax, maximal [18F]FET tumor to background ratio; PRM, parametric response mapping; RANO, response assessment in neuro-oncology; ROC, receiver operating characteristics; AUC, area under curve. Δ and rΔ denote the absolute and relative change from the baseline.